Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.45 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | LIPC | P11150 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134578 | 0.95 | MKNK1 (0.46) | MKNK1MKNK2RARBFYNCSNK2A2 | |
| SCHEMBL6132394 | 0.92 | MKNK1 (0.46) | MKNK1MKNK2FYNCSNK2A2CSNK2A1 | |
| SCHEMBL6132170 | 0.92 | MKNK1 (0.45) | MKNK1MKNK2FYNCSNK2A2CSNK2A1 | |
| SCHEMBL6135026 | 0.91 | MKNK1 (0.47) | MKNK1MKNK2FYNUSP2PIM1 | |
| SCHEMBL6135144 | 0.91 | MKNK1 (0.47) | MKNK1MKNK2FYN | |
| SCHEMBL6134597 | 0.85 | MKNK1 (0.48) | MKNK1MKNK2RARBFYN | |
| SCHEMBL6135503 | 0.84 | CSNK2A2 (0.52) | RARBCSNK2A2CSNK2A1USP2LIPC | |
| SCHEMBL6134954 | 0.83 | MKNK1 (0.47) | MKNK1MKNK2FYNCSNK2A2CSNK2A1 | |
| SCHEMBL6132627 | 0.83 | MKNK1 (0.48) | MKNK1MKNK2FYNUSP2PIM1 | |
| SCHEMBL7326113 | 0.82 | RARB (0.55) | MKNK1MKNK2RARBFYNCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | MKNK1 2695/4885MKNK2 3220/4885RARB 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.